+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Aricept"

From
Alzheimer's Drugs Market Report 2025 - Product Thumbnail Image

Alzheimer's Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Dementia Associated With Alzheimer's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Dementia Associated With Alzheimer's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Alzheimer's Treatment Market Report and Forecast 2025-2034 - Product Thumbnail Image

Alzheimer's Treatment Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
Alzheimer's Disease Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Alzheimer's Disease Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Aricept is a drug used to treat Alzheimer's Disease, a progressive neurological disorder that affects memory, thinking, and behavior. It is a cholinesterase inhibitor, meaning it works by increasing the amount of a chemical messenger in the brain that is involved in memory and thinking. Aricept is the most commonly prescribed drug for Alzheimer's Disease, and is used to slow the progression of the disease and improve cognitive function. It is available in both immediate-release and extended-release forms, and is taken orally. The Aricept market is highly competitive, with many companies offering similar products. Some of the major players in the market include Pfizer, Eisai, Novartis, and Mylan. Other companies such as Sun Pharmaceuticals, Teva Pharmaceuticals, and Dr. Reddy's Laboratories also offer generic versions of Aricept. Show Less Read more